Pioneering the chemistry of early detection.
DatChem is addressing unmet patient needs through analysis of patient data on a cloud-based platform, leading to earlier interventions and better patient outcomes.
A clinical breakthrough, two decades in the making.
Scientific and clinical research into MRS technology has been performed by the founders of DatChem over more than two decades.
They created the new DatChem protocol for data acquisition and a cloud-hosted, scalable data-analysis application, enabling DatChem to measure, non-invasively, the level of specific disease biomarkers. In doing so, DatChem has made a clinical breakthrough in the application of Magnetic Resonance Spectroscopy (MRS).
We believe this technology will change the way doctors and other health practitioners identify, diagnose and treat disease.
Advanced procedures, no new hardware.
DatChem extends what magnetic resonance can do, turning a routine scan into a non-invasive read of tissue chemistry, interpreted in the cloud.
Magnetic Resonance Spectroscopy
A clinical breakthrough in the application of MRS, reading the chemistry of tissue from a standard scan, with no contrast and no biopsy.
Cloud-hosted analysis
DatChem's proprietary cloud-hosted data analysis application measures the level of specific disease biomarkers against exclusive databases.
Cloud-based platform
A scalable, secure cloud application interprets each study in minutes, with data sovereignty respected on a regional basis.
Board of Directors.
Carolyn Mountford
David Purdue
Tim McLennan
James Malycha
Sarah Mountford-Bunn
Andrew Mountford-Bunn
Sue Jeavons
David Clark
The DatChem Team.
Clinicians, scientists, engineers and advocates building the future of early detection.
Peter Malycha
Gorane Santamaria
John Irvine
David Crompton
Rosanna Tremewan
Jason Beard
Julia Watson
Laurie Kear
Dr. Budi Jap
Lisa Rich
Darren Lukas
Natali Naude
Tyrone Humphries
Graham Galloway
Neha Chaudhary
Wendy Dean
Proof, in the clinic and the lab.
DatChem is on track for FDA and TGA approvals, with sites in Australia and Europe.
- Longitudinal breast study completed (2012–2024), 31 of 32 cancers correctly predicted.
- PTSD & blast-overpressure trial completed, funded by the USA CTTSO.
- SaaS platform built and operating in the cloud.
- Clinical sites live in Australia and Europe.
- Regulatory approval: on track for FDA approval, with TGA & EMA to follow.
- Siemens Healthineers: a relationship since 1999, formalised by a 2026 LOI.
- ADHD clinical trial: beginning in Australia, with intent to progress globally.
- Commercialisation across selected global markets.
Built to medical-device standard.
A commercial quality management system governs the structure, procedures and resources behind DatChem, covering every step from the moment data leaves the scanner to the report posted back to the PACS, for compliance with FDA, EMA and TGA requirements.
Quality management systems
Medical devices, quality management systems, requirements for regulatory purposes.
Risk management
Medical devices, the application of risk management to medical devices.
Software life cycle
Medical device software, software life-cycle processes, governing data from scanner to report.
Siemens Healthineers is assisting with this process, alongside any further ISO standards applicable to our software device.
Current clinical & research collaborators
A robust portfolio across the US, EU & Australia.
Nine granted patents and twelve registered applications spanning breast-cancer detection, PTSD, pain, ADHD and the underlying spectroscopy architecture, backed by an international patent strategy.
The full patent portfolio.
Every granted patent and registered application, across the US, EU and Australia.
Granted patents
| Patent | Granted | Title |
|---|---|---|
| US 8404487 | 2008 | MRS of breast biopsy to determine pathology, vascularisation and nodal involvement |
| US 8755862 | 2014 | Detecting pain and its components using magnetic resonance |
| US 11096621 | 2021 | Detection of BRCA and other high-risk carriers in breast tissue |
| US 11346909 | 2022 | Systems architecture for analysis of spectroscopy & fMRI using integrated classifiers |
| US 11723590 | 2023 | Detecting & identifying acute pain, its transition to chronic pain, and monitoring therapy |
| US 12109035 | 2024 | Treating and monitoring post-traumatic stress disorder (PTSD) |
| EU · no. pending | 2025 | Detection of BRCA and other high-risk carriers in breast tissue |
| USA · no. pending | 2025 | Acquiring spectral data from healthy breast tissue to detect breast-cancer development |
| EU · no. pending | 2026 | Acquiring spectral data from healthy breast tissue to detect breast-cancer development |
Patent applications
| Application | Title |
|---|---|
| US 2019/0125257 | Detecting and monitoring PTSD using MRS |
| US 2020/0029816 | Detecting and identifying acute stress response from trauma, its transition to PTSD, and monitoring therapy |
| US 2020/0008741 | Detecting and identifying acute pain, its transition to chronic pain, and monitoring therapy |
| US 2020/0129110 | Functional analysis of the brain using fMRI for acute stress and PTSD, monitoring neuroplasticity |
| US 2020/0229757 | Monitoring treatment for acute pain, chronic pain, acute stress, blast exposure or PTSD from brain spectral data |
| US 2020/0178889 | Detecting levels of pain using MRS |
| US 2017/0172495 | Detecting and identifying different types of pain and monitoring therapy |
| US 2020/0261012 | Treating and monitoring PTSD |
| US 2022/0202374 | Acquiring spectral data to assess breast-cancer risk |
| US 16/503,052 | Detecting and identifying acute pain, its transition to chronic pain, and monitoring therapy |
| AU 2021411096 | Acquiring spectral data to assess breast-cancer risk |
| US 63/Z755,119 | Detecting ADHD using spectral data of the brain, and monitoring treatment |
Better care through DatChem.
For clinical, commercial, partnership or investment enquiries, our team would be glad to hear from you.